Metabolon Introduces MVision(TM)

Metabolon, Inc.,
the leader in metabolomics solutions for drug development and the discovery
of new diagnostic markers today announced the launch of mVision, an
integrated service providing the biomarker discovery, biochemical pathway
analysis, and biological effect intelligence needed by scientists to
confidently and effectively advance their research programs.


Based on Metabolon's advanced analytic and informatics platforms,
mVision is designed to identify biochemical biomarkers from numerous
chemical classes and various sample matrices including: plasma, serum,
urine, cerebrospinal fluid (CSF), cell extracts, and tissues. mVision's
unbiased and non-targeted approach to biomarker discovery allows scientists
to observe drug- or disease- induced biochemical changes over virtually the
entire spectrum of biochemical pathways. This global screening can be
accomplished without hypotheses of the biologic or biochemical effects of
disease or the investigational drug.



"Together with Metabolon's other solutions, mSelect(TM), mVivo(TM), and
mProveClinical(TM), mVision provides scientists with the unified biomarker
discovery and pathway analysis platform they need to understand disease
processes and to evaluate drug effects throughout their in vitro, in vivo,
and human clinical studies," said Dr. John Ryals, president and CEO of
Metabolon. "Because biochemical biomarkers are highly conserved between
species, findings from early discovery research can be translated to
predict results of later studies, including human clinical trials."



"With mVision, Metabolon continues to lead the evolution of
metabolomics by extending biochemical signal detection to biomarker
identification," said Ryals. "With Metabolon's family of discovery
solutions, researchers can more effectively discover biomarkers for disease
detection, prognosis, and therapeutic monitoring as well as biomarkers
associated with drug toxicity and efficacy."



About Metabolon



Metabolon is the industry leader in the discovery of biomarkers through
the use of metabolomics, a powerful scientific approach for the discovery
and development of drugs and the early diagnosis of disease. Metabolon's
patented technology dramatically impacts drug discovery and development
processes by accurately measuring the spectrum of biochemical changes and
mapping these changes to metabolic pathways. Metabolon's technology can
identify safer compounds for development, shorten a drug's time to market
and identify novel biomarkers for earlier disease detection. In 2006,
Metabolon was awarded a patent that broadly covers the metabolomic methods
used to identify biomarkers seen in patients with amyotrophic lateral
sclerosis (ALS). For additional information, visit
metabolon.


Metabolon, Inc.

metabolon